Feb. 17 at 6:09 PM
$IMMX
Read the tape. Not the noise.
Float: ~39.7M
Short: ~3M shares (+32% increase)
Market cap:
$388M
Now overlay this with the 13Fs that just dropped.
Janus. Saturn V. Eventide. Adage. Marshall Wace. Goldman. Renaissance. Vanguard.
That’s not “let’s see what happens” sizing.
That’s conviction.
So let me get this straight…
Institutions are locking up millions of shares
Shorts are pressing into it
Float is sub-40M
Company has RMAT + BTD + BLA pathway clarity
Tons of cash. Well over
$100M
And we’re still under
$400M?
If this thing gets even a modest biotech rerate, 3M short shares have to fight for supply that’s increasingly in strong hands.
That’s how squeezes start.
Not from memes.
From math.
Risk/reward here is wildly asymmetric.
Structure is tightening.
Pressure is building.
